Abstract:Parkinson's disease (PD) is among the most prevalent neurodegenerative disorders, affecting over 10 million people worldwide. The protein encoded by the SNCA gene, alpha‐synuclein (ASYN), is the major component of Lewy body (LB) aggregates, a histopathological hallmark of PD. Mutations and posttranslational modifications (PTMs) in ASYN are known to influence protein aggregation and LB formation, possibly playing a crucial role in PD pathogenesis. In this work, we applied computational methods to characterize the effects of missense mutations and PTMs on the structure and function of ASYN. Missense mutations in ASYN were compiled from the literature/databases and underwent a comprehensive predictive analysis. Phosphorylation and SUMOylation sites of ASYN were retrieved from databases and predicted by algorithms. ConSurf was used to estimate the evolutionary conservation of ASYN amino acids. Molecular dynamics (MD) simulations of ASYN wild‐type and variants A30G, A30P, A53T, and G51D were performed using the GROMACS package. Seventy‐seven missense mutations in ASYN were compiled. Although most mutations were not predicted to affect ASYN stability, aggregation propensity, amyloid formation, and chaperone binding, the analyzed mutations received relatively high rates of deleterious predictions and predominantly occurred at evolutionarily conserved sites within the protein. Moreover, our predictive analyses suggested that the following mutations may be possibly harmful to ASYN and, consequently, potential targets for future investigation: K6N, T22I, K34E, G36R, G36S, V37F, L38P, G41D, and K102E. The MD analyses pointed to remarkable flexibility and essential dynamics alterations at nearly all domains of the studied variants, which could lead to impaired contact between NAC and the C‐terminal domain triggering protein aggregation. These alterations may have functional implications for ASYN and provide important insight into the molecular mechanism of PD, supporting the design of future biomedical research and improvements in existing therapies for the disease.

Elucidating the Molecular Basis of 14-3-3 Interaction with α-Synuclein: Insights from Molecular Dynamics Simulations and the Design of a Novel Protein-Protein Interaction Inhibitor

Identification of novel proteins interacting with both α-synuclein and DJ-1

Identification of Novel Proteins Associated with Both α-Synuclein and DJ-1

Identification of novel proteins associated with both alpha-synuclein and DJ-1.

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

Protein–protein interactions regulating α-synuclein pathology

Broad proteomics analysis of seeding-induced aggregation of α-synuclein in M83 neurons reveals remodeling of proteostasis mechanisms that might contribute to Parkinson's disease pathogenesis

Interplay between α-synuclein and parkin genes: Insights of Parkinson's disease

In silico analysis of alpha‐synuclein protein variants and posttranslational modifications related to Parkinson's disease

Exploring α-synuclein Interaction Partners and their Potential Clinical Implications for Parkinson's Disease

1,4-Diurea- and 1,4-Dithiourea-Substituted Aromatic Derivatives Selectively Inhibit α-Synuclein Oligomer Formation In Vitro

Prediction of Inhibitors Against Alpha-Synuclein Fibrils Formed in Parkinson’s Disease

[Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].

Molecular Chaperones, Alpha-Synuclein, and Neurodegeneration

Development of Alpha-Synuclein protein model against therapeutic aspects of Parkinson’s disease

Modulation of -Synuclein Aggregation Amid Diverse Environmental Perturbation

Alpha-Synuclein Aggregation in Parkinson's Disease

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

Modulation of α-synuclein aggregation amid diverse environmental perturbation

Inhibitor Development for α-Synuclein Fibril's Disordered Region to Alleviate Parkinson's Disease Pathology

Probing the molecular mechanisms of α-synuclein inhibitors unveils promising natural candidates through machine-learning QSAR, pharmacophore modeling, and molecular dynamics simulations